Share：
Share this content in WeChat
X
[Chinese][PDF]5981
• Original Article •
Study of targeting fibrin polypeptide nanoprobes in enhanced MRI for venous thrombosis
WU Hongyun  SHI Yonggui  LIAO Yukun  HE Honglin  ZHONG Yixin 

Cite this article as: Wu HY, Shi YG, Liao YK, et al. Study of targeting fibrin polypeptide nanoprobes in enhanced MRI for venous thrombosis[J]. Chin J Magn Reson Imaging, 2022, 13(12): 117-123. DOI:10.12015/issn.1674-8034.2022.12.020.


[Abstract] Objective The individualized treatment of patients with venous thromboembolism is closely related to their good prognosis, and accurate diagnosis is necessary for the correct formulation of treatment plans. Given the high biological safety of ferric oxide and polylactic hydroxyacetic acid (PLGA), we designed a nanoprobe (NP) of ferric oxide polylactic hydroxyacetic acid pentapeptide (Fe3O4-PLGA-CREKA) to improve the detection ability of thrombus through targeting fibrin.Materials and Methods Fe3O4-PLGA-CREKA nanoprobes were made by double emulsification and carbodiimide, and their physicochemical properties were tested. In-vitro magnetic resonance imaging (MRI) of Fe3O4-PLGA-CREKA nanoprobe was performed with T2WI and T2 mapping sequences to analyze the correlation between nanoprobe concentration and T2 relaxation rate. The venous blood of rats was collected to make frozen sections and incubated with Fe3O4-PLGA/DiI CREKA NPs (targeted group) and Fe3O4-PLGA/DiI NPs (non-targeted group) respectively. The targeting of different nanoprobes to thrombus was observed by inverted fluorescent microscope. After the safety verification of the nanoprobe on cells, a venous thrombosis model was established in the jugular vein of SD rats. Fe3O4-PLGA-CREKA NP (targeted group) and Fe3O4-PLGA NP (non-targeted group) were injected into the caudal vein respectively. Data were collected after T2WI and T2 mapping sequence scanning. At the same time, major organs were collected, and the safety of the nanoprobe was verified by H&E staining.Results In this study, Fe3O4-PLGA-CREKA nanoprobes with a particle size of (255.3±56.0) nm were successfully prepared, and their surface potential was (-18.90±5.84) mV; The TEM results showed that the nanoprobe was a homogeneous sphere with good dispersion; The nanoprobes had the ability to enhance MR signal; Compared with the non-targeted group, the targeted group's nanoprobes can better target venous thrombosis, which has good biosafety; the T2 relaxation rates of non-targeted group and the targeted group before and after administration were (17.33±2.25) s-1, (49.00±6.66) s-1, (19.00±3.90) s-1 and (72.83±6.68) s-1, respectively.Conclusions The Fe3O4-PLGA-CREKA nanoprobes prepared in our study possess good biosafety and MRI imaging ability with high specificity for venous thrombosis, which is expected to help with venous thromboembolism diagnosis and treatment in the future.
[Keywords] nanoprobe；thrombus targeting；magnetic resonance imaging；pentapeptide；multimodal imaging

WU Hongyun   SHI Yonggui   LIAO Yukun   HE Honglin   ZHONG Yixin*  

Department of Radiology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

Zhong YX, E-mail: zhongyixin@hospital.cqmu.edu.cn

Conflicts of interest   None.

ACKNOWLEDGMENTS Postdoctoral Natural Science Foundation of Chongqing (No. cstc2021jcyj-bshX0136); China Postdoctoral Science Foundation (No. 2019M663891XB); The Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University (No. kryc-gg-2213).
Received  2022-07-06
Accepted  2022-11-29
DOI: 10.12015/issn.1674-8034.2022.12.020
Cite this article as: Wu HY, Shi YG, Liao YK, et al. Study of targeting fibrin polypeptide nanoprobes in enhanced MRI for venous thrombosis[J]. Chin J Magn Reson Imaging, 2022, 13(12): 117-123. DOI:10.12015/issn.1674-8034.2022.12.020.

[1]
Renner E, Barnes GD. Antithrombotic management of venous thromboembolism: JACC focus seminar[J]. J Am Coll Cardiol, 2020, 76(18): 2142-2154. DOI: 10.1016/j.jacc.2020.07.070.
[2]
Vincent LE, Talanker MM, Butler DD, et al. Association of changes in antithrombin activity over time with responsiveness to enoxaparin prophylaxis and risk of trauma-related venous thromboembolism[J]. JAMA Surg, 2022, 157(8): 713-721. DOI: 10.1001/jamasurg.2022.2214.
[3]
Ahmed O, Cifu AS, Paul J. Inferior vena cava filters for the treatment of patients with venous thromboembolic disease[J]. JAMA, 2021, 326(13): 1321-1322. DOI: 10.1001/jama.2021.9262.
[4]
Bikdeli B, Zahedi Tajrishi F, Sadeghipour P, et al. Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review[J]. JAMA Cardiol, 2022, 7(7): 747-759. DOI: 10.1001/jamacardio.2022.1292.
[5]
McCormack T, Harrisingh MC, Horner D, et al. Venous thromboembolism in adults: summary of updated NICE guidance on diagnosis, management, and thrombophilia testing[J/OL]. BMJ, 2020, 369: m1565 [2022-07-05]. https://doi.org/10.1136/bmj.m1565. DOI: 10.1136/bmj.m1565.
[6]
Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism[J]. Blood Adv, 2020, 4(19): 4693-4738. DOI: 10.1182/bloodadvances.2020001830.
[7]
Vascular Surgery Group, Surgical Society of Chinese Medical Association. Guidelines for the diagnosis and treatment of deep vein thrombosis (3rd edition)[J]. Chin J Vasc Surg Electron Version, 2013, 5(1): 23-26. DOI: 10.3969/j.issn.1674-7429.2013.01.009.
[8]
Expert Committee on Chinese Guidelines for the Prevention and Treatment of Thrombotic Diseases. Chinese guidelines for the prevention and treatment of thrombotic diseases[J]. Chin Med J, 2018, 98(36): 2861-2888. DOI: 10.3760/cma.j.issn.0376-2491.2018.36.002.
[9]
Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer[J/OL]. Lancet Oncol, 2019, 20(10): e566-e581 [2022-07-05]. https://doi.org/10.1016/S1470-2045(19)30336-5. DOI: 10.1016/S1470-2045(19)30336-5.
[10]
Chopard R, Albertsen IE, Piazza G. Diagnosis and treatment of lower extremity venous thromboembolism: a review[J]. JAMA, 2020, 324(17): 1765-1776. DOI: 10.1001/jama.2020.17272.
[11]
Dam LFV, Dronkers CEA, Gautam G, et al. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis[J]. Blood, 2020, 135(16): 1377-1385. DOI: 10.1182/blood.2019004114.
[12]
Wen AM, Wang YM, Jiang K, et al. Shaping bio-inspired nanotechnologies to target thrombosis for dual optical-magnetic resonance imaging[J]. J Mater Chem B, 2015, 3(29): 6037-6045. DOI: 10.1039/C5TB00879D.
[13]
Kim J, Park JE, Nahrendorf M, et al. Direct Thrombus imaging in stroke[J]. J Stroke, 2016, 18(3): 286-296. DOI: 10.5853/jos.2016.00906.
[14]
Stein-Merlob AF, Kessinger CW, Erdem SS, et al. Blood accessibility to fibrin in venous thrombosis is Thrombus age-dependent and predicts fibrinolytic efficacy: an in vivo fibrin molecular imaging study[J]. Theranostics, 2015, 5(12): 1317-1327. DOI: 10.7150/thno.12494.
[15]
Andia ME, Saha P, Jenkins J, et al. Fibrin-targeted magnetic resonance imaging allows in vivo quantification of thrombus fibrin content and identifies thrombi amenable for thrombolysis[J]. Arterioscler Thromb Vasc Biol, 2014, 34(6): 1193-1198. DOI: 10.1161/ATVBAHA.113.302931.
[16]
Zhong YX, Ye M, Huang LD, et al. A fibrin site-specific nanoprobe for imaging fibrin-rich thrombi and preventing Thrombus formation in venous vessels[J/OL]. Adv Mater, 2022, 34(16): e2109955 [2022-07-05]. https://doi.org/10.1002/adma.202109955. DOI: 10.1002/adma.202109955.
[17]
Xu J, Zhou J, Zhong YX, et al. Phase transition nanoparticles as multimodality contrast agents for the detection of thrombi and for targeting thrombolysis: in vitro and in vivo experiments[J]. ACS Appl Mater Interfaces, 2017, 9(49): 42525-42535. DOI: 10.1021/acsami.7b12689.
[18]
Li YY, Na RW, Wang XM, et al. Fabrication of antimicrobial peptide-loaded PLGA/chitosan composite microspheres for long-acting bacterial resistance[J/OL]. Molecules, 2017, 22(10): 1637 [2022-07-05]. https://doi.org/10.3390/molecules22101637. DOI: 10.3390/molecules22101637.
[19]
Khan F, Tritschler T, Kahn SR, et al. Venous thromboembolism[J]. Lancet, 2021, 398(10294): 64-77. DOI: 10.1016/S0140-6736(20)32658-1.
[20]
Zhao Y, Xie RS, Yodsanit N, et al. Biomimetic fibrin-targeted and H2O2-responsive nanocarriers for thrombus therapy[J/OL]. Nano Today, 2020, 35: 100986 [2022-07-05]. https://doi.org/10.1016/j.nantod.2020.100986. DOI: 10.1016/j.nantod.2020.100986.
[21]
Temme S, Grapentin C, Quast C, et al. Noninvasive imaging of early venous thrombosis by 19F magnetic resonance imaging with targeted perfluorocarbon nanoemulsions[J]. Circulation, 2015, 131(16): 1405-1414. DOI: 10.1161/CIRCULATIONAHA.114.010962.
[22]
O'Brien AT, Gil KE, Varghese J, et al. T2 mapping in myocardial disease: a comprehensive review[J/OL]. J Cardiovasc Magn Reson, 2022, 24(1): 33 [2022-06-06]. https://doi.org/10.1186/s12968-022-00866-0. DOI: 10.1186/s12968-022-00866-0.
[23]
Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery[J]. Nat Rev Drug Discov, 2021, 20(2): 101-124. DOI: 10.1038/s41573-020-0090-8.
[24]
Song YN, Huang ZY, Xu JF, et al. Multimodal SPION-CREKA peptide based agents for molecular imaging of microthrombus in a rat myocardial ischemia-reperfusion model[J]. Biomaterials, 2014, 35(9): 2961-2970. DOI: 10.1016/j.biomaterials.2013.12.038.
[25]
Zhong YX, Zhang Y, Xu J, et al. Low-intensity focused ultrasound-responsive phase-transitional nanoparticles for thrombolysis without vascular damage: a synergistic nonpharmaceutical strategy[J]. ACS Nano, 2019, 13(3): 3387-3403. DOI: 10.1021/acsnano.8b09277.
[26]
Allahyari M, Mohit E. Peptide/protein vaccine delivery system based on PLGA particles[J]. Hum Vaccines Immunother, 2016, 12(3): 806-828. DOI: 10.1080/21645515.2015.1102804.
[27]
Overoye-Chan K, Koerner S, Looby RJ, et al. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus[J]. J Am Chem Soc, 2008, 130(18): 6025-6039. DOI: 10.1021/ja800834y.
[28]
Ye M, Zhou J, Zhong YX, et al. SR-A-targeted phase-transition nanoparticles for the detection and treatment of atherosclerotic vulnerable plaques[J]. ACS Appl Mater Interfaces, 2019, 11(10): 9702-9715. DOI: 10.1021/acsami.8b18190.
[29]
Cui C, Yang Z, Hu X, et al. Organic semiconducting nanoparticles as efficient photoacoustic agents for lightening early Thrombus and monitoring thrombolysis in living mice[J]. ACS Nano, 2017, 11(3): 3298-3310. DOI: 10.1021/acsnano.7b00594.
[30]
Wang TT, Yuan CX, Dai BY, et al. Click-chemistry-mediated rapid microbubble capture for acute Thrombus ultrasound molecular imaging[J]. ChemBioChem, 2017, 18(14): 1364-1368. DOI: 10.1002/cbic.201700068.

PREV Quantitative assessment of arterial wall by magnetic resonance 3D DANTE CUBE sequence: An experimental study compared with pathology
NEXT An imaging study of three-dimensional simultaneous non-contrast angiography and intraplaque hemorrhage of whole brain based on compressed sensing
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn